In order to implement the spirit of the 20th National Congress of the Party and the important instructions of General Secretary Xi Jinping, implement the various work requirements in the special work plan of the All-China Federation of Trade Unions’ “County-Level Trade Union Strengthening Year”, vigorously promote the spirit of “Great Country Craftsmen”, and consolidate the high level of our district The Nanshan District Federation of Trade Unions will continue to hold the 2023 Nanshan District “Top Ten Innovative Craftsmen” selection event on the basis of the four successful selection events held from 2019 to 2022.
On November 10, 2023, the list of the “Top Ten Innovative Craftsmen” in Nanshan District in 2023 was officially announced. Dr. Liao Yan from the R&D Center of Shenzhen Beike Biotechnology Co., Ltd. and other 10 outstanding talents stood out from 134 candidates and won this honor!
This time, the selection of Nanshan District’s “Top Ten Innovative Craftsmen” focused on Nanshan District’s “14+7” strategic emerging industry clusters and future industries, attracting the participation of many highly sophisticated, highly educated and highly technical talents, including 105 industries. 134 innovative talents from leading enterprises in the industry, specialized and new “little giant” enterprises, and unicorn enterprises applied to participate in the evaluation. After fierce competition in preliminary evaluation data review, re-evaluation on-site inspection, online voting, and online final evaluation defense, the candidates for the “Top Ten Innovative Craftsmen” were finally selected.
Nanshan District’s “Top Ten Innovative Craftsmen”
Deputy Director, Beike Biological R&D Center
Graduated from Sun Yat-sen University with a Ph.D. in 2019“Shenzhen high-level professional talents (reserve level)” title, was rated as a Guangdong Province Enterprise in 2022“Innovation Expert”, awarded in 2023“Pengcheng Talent Card” cardholders. Published 23 scientific research papers in domestic and foreign magazines such as Molecular Therapy, including 7 first authors/co-first authors and 1 co-corresponding author. Obtained 3 authorized invention patents and 2 authorized utility model patents. As the first person in charge, he is responsible for 6 national-level local natural science funds, including the National Key Research and Development Program sub-project (1 project), the National Natural Science Foundation (1 project), and the Guangdong Provincial Natural Science Foundation (2 projects).
Dr. Liao Yan chose the basic medical stem cell major during his master’s degree at Sun Yat-sen University. Later, under the guidance of his doctoral supervisor Professor Xiang Peng for many years, he determined the direction of his doctoral topic – the study of the mechanisms of mesenchymal stem cells in the treatment of various diseases. This also laid the foundation for his future long-term development in the field of biomedicine – “cells and genes”.
After Dr. Liao Yan joined Beike Biotech in 2019, as the R&D project leader, he is mainly responsible for the development of new stem cell technologies and IND filing for new drugs. On the one hand, in order to improve technical barriers and product performance, stem cell “empowerment” technology has been developed, this technology can enhance certain specific functions of mesenchymal stem cells, improve clinical efficacy, and apply for 3 invention patents to the Patent Office;On the other hand, he actively participated in the process development of the company’s umbilical cord mesenchymal stem cell injection products, pharmacological and toxicological evaluation and other work are in progress, and an IND application has been submitted to the Food and Drug Administration. It is expected to launch clinical trials for severe refractory systemic lupus erythematosus after obtaining clinical approval in 2024. In the future, Liao Yan hopes to bring second-generation products such as “empowered mesenchymal stem cells” to the market to achieve economic and social value. At the same time, his team is developing induced pluripotent stem cell (iPSC) technology, and cell products derived from iPSC differentiation will achieve product characteristics of large-scale production, good stability and strong functionality, and will have broad room for development in the future.